|Bid||14.00 x 4000|
|Ask||15.05 x 800|
|Day's Range||14.44 - 14.83|
|52 Week Range||11.55 - 27.33|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.70|
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
The Morris Plains, New Jersey-based company said it had a loss of 46 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of.
Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, May 9, 2019 at 8:00 a.m. Eastern Time to discuss financial results for the first quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) and Everest Medicines II Limited (“Everest Medicines”), a C-Bridge Capital-backed biopharmaceutical company, today announced an exclusive license agreement to develop, register, and commercialize sacituzumab govitecan in Greater China, South Korea and certain Southeast Asian countries (Territory). “We are pleased to be partnering with Everest Medicines to commercialize sacituzumab govitecan in the Asian market outside Japan and further develop the product in solid tumor indications of high unmet need in the territory,” said Usama Malik, Chief Financial Officer and Chief Business Officer of Immunomedics.
“I am proud to have been part of Immunomedics and have full confidence in the capabilities of the team to bring sacituzumab govitecan to patients in a timely manner and help patients with difficult-to-treat cancers across the U.S. and the world. My decision comes after careful consideration and is driven by my personal priorities and a desire to be close to my family after many years of having worked far away from home,” commented Dr. Rob Iannone. Behzad Aghazadeh, Executive Chairman of Immunomedics, commented, “We thank Rob for his service to the Company, and wish him well in his new endeavors.
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
Today we will run through one way of estimating the intrinsic value of Immunomedics, Inc. (NASDAQ:IMMU) by taking the expected future cash flows and discounting them to their present value. I will be using the Discounted Cash...
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it has entered into a promotion agreement in which Immunomedics will provide detailing services to Janssen Biotech Inc. (Janssen), for erdafitinib in the U.S. “We are delighted to be collaborating with Janssen and we look forward to working closely with the Janssen team to help promote erdafitinib," said Brendan Delaney, Chief Commercial Officer of Immunomedics.
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 25.69% for Immunomedics (IMMU) based on the company’s closing price on
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the appointment of Barbara G. Duncan to the Company’s Board of Directors and as the Chairperson of the Audit Committee. Ms. Duncan has over 30 years of financial leadership experience, of which 17 are in the life sciences industry. “We are honored to have Barbara join our Board.
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in a fireside chat at Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 2:10 p.m. Eastern Time at the Boston Marriott Copley Place, Boston, MA. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at the conference.
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
SAN DIEGO, Feb. 26, 2019 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: IMMU shares over alleged securities laws.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
NEW YORK, Feb. 25, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
Preparation for Resubmission of BLA for Sacituzumab Govitecan Continuing Phase 2 Data in mTNBC Published in New England Journal of Medicine Oral Presentation of Updated Phase.
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the ...
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.